Next Article in Journal
The Design of 3D-Printed Polylactic Acid–Bioglass Composite Scaffold: A Potential Implant Material for Bone Tissue Engineering
Previous Article in Journal
2,4-Dinitrophenol as an Uncoupler Augments the Anthracyclines Toxicity against Prostate Cancer Cells
Previous Article in Special Issue
BSA Interaction, Molecular Docking, and Antibacterial Activity of Zinc(II) Complexes Containing the Sterically Demanding Biomimetic N3S2 Ligand: The Effect of Structure Flexibility
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Complex-Forming Properties of Ceftazidime with Fe(III) Ions in an Aqueous Solution

1
Department of Physical and Biocoordination Chemistry, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland
2
Department of Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland
*
Author to whom correspondence should be addressed.
Molecules 2022, 27(21), 7226; https://doi.org/10.3390/molecules27217226
Submission received: 29 September 2022 / Revised: 19 October 2022 / Accepted: 21 October 2022 / Published: 25 October 2022
(This article belongs to the Special Issue New Trends in Developing Complexes as Biological Active Species)

Abstract

:
In the present study, the complexing properties of ceftazidime with Fe(III) ions in aqueous solutions were characterized by UV-vis spectrophotometric and potentiometric methods. Using the UV-vis spectrophotometric method, the absorbance values for Fe(III) ions, a third-generation cephalosporin antibiotic (ceftazidime), and the Fe(III)-ceftazidime system were determined. Based on pH-metric studies, the value of the stability constant for the Fe(III)-ceftazidime complex was calculated.

1. Introduction

Iron(III) ion is the fourth most important transition metal ion in biological systems [1]. It is an essential micronutrient for humans, with critical functions in many cellular processes, including DNA synthesis, replication, repair, and transcription [2]. Iron functions as a redox catalyst and occurs as ferrous Fe2+ or ferric Fe3+ inside the cell [3,4]. The deficiency of iron decreases oxygen delivery to cells, resulting in fatigue, poor work performance, and decreased immune function [5]. Excess amounts of Fe(III) ions in a living cell can catalyse the production of reactive oxygen species through the Fenton reaction, which can damage lipids, nucleic acids, and proteins. The cellular toxicity of Fe(III) contributes to serious diseases, like Huntington’s, Alzheimer’s, and Parkinson’s diseases [6].
Ceftazidime (Figure 1) is a third-generation cephalosporin antibiotic usually reserved for the treatment of infections caused by Pseudomonas aeruginosa. It is also used in combination with other antibiotics for the empirical treatment of febrile neutropenia [7,8]. In general, cephalosporins are usually bactericidal against susceptible bacteria and act by inhibiting mucopeptide synthesis in the cell wall, resulting in a defective barrier and an osmotically unstable spheroplast [9]. The mechanism for this effect has not been definitively determined, but beta-lactam antibiotics have been shown to bind to several enzymes (carboxypeptidases, transpeptidases, endopeptidases) within the bacterial cytoplasmic membrane that is involved in the cell wall synthesis [10].
Many cephalosporin antibiotics form stable complexes with d-metal cations. Studying the metal complexes of antibiotics is of interest for both the design of new combined drugs and the development of new procedures of drug analysis based on complexation reactions. By the present time, solid M(Ctzd)Cl ceftazidime complexes, where M = Mn(II), Fe(II), Co(II), Ni(II), Cu(II), or Cd(II), have been obtained as precipitates from methanol solutions. Elemental analyses agree with a 1:1 metal to ligand stoichiometry for all the complexes. The manganese(II) and cobalt(II) complexes are beige and dark red, respectively, while the iron(II), nickel(II), and copper(II) complexes are green. The cadmium(II) complex is white, and the complexes are air-stable solids that are insoluble in H2O and other common organic solvents such as EtOH, benzene, acetone, acetonitrile, ether, DMF, and DMSO. The general formula [M(ceftaz)(H2O)Cl] has been assigned to the complexes. The insolubility and high melting points of the complexes (4300 °C) suggest that they are polymeric. Thermograms of the hydrated metal complexes indicate endothermic decompositions in the 150–160 °C range due to the loss of coordinated water and also reveal that the complexes are stable and have no hydration water or solvent [11]. The synthesis and spectrophotometric and electrochemical characterization of the complexation of Schiff base (ceftazidime “CFZ”-p-dimethylaminobenzaldehyde “DAB”) with Cu(II), Co(II), Ni(II), Fe(III), and Ru(III) ions is also described. The obtained precipitates were filtered, washed with methanol, and dried in the air. The analytical data show the composition of the metal complex to be [M(CFZ-DAB)Cln]Cl, where CFZ-DAB is the Schiff base ligand; n = 1 for the Cu(II), Co(II), and Ni(II) complexes; and n = 2 for the Fe(III) and Ru(III) complexes. The conductance data indicate that all the complexes are strong electrolytes. The compound (CFZ-DAB) behaves as a tridentate ligand. However, the obtained complexes have a mononuclear nature. The electrochemical properties of the metal complexes were investigated by cyclic voltammetry (CV) using glassy carbon electrode. The oxidation/reduction of metal complexes was irreversible/reversible and exhibited a diffusion-controlled process depending on the pH. The dependence of intensities of currents and potentials on the pH, concentration, scan rate, and nature of the buffer was investigated [12].
This work aimed to evaluate the complexation properties of a cephalosporin antibiotic (ceftazidime) with Fe(III) ions in an aqueous solution. The absorbance values for Fe(III) ions, ceftazidime, and the Fe(III)-ceftazidime system were determined by the UV-vis spectrophotometric method. The value of the stability constant for the Fe(III)-ceftazidime system was calculated using the potentiometric method.

2. Results and Discussion

The electronic absorption spectra for ceftazidime water solution in the range of 200–360 nm revealed absorbance features at ca. 235sh, 257, 283sh, and 300sh nm within the pH range of 1.82–12.03 (Figure 2a). The presence of isosbestic points (at ca. 235, 245, 250, and 300 nm) confirms the existence of equilibria between the various deprotonated forms of ceftazidime [13,14].
The electronic absorption spectra for the Fe(III) chloride water solution in the range of 250–500 nm revealed absorbance features at ca. 337 nm at the pH 0.97 (Figure 2b). The hydrolysis of the Fe(III) ions was already observed above pH 1.0 and corresponded to the literature data. As indicated by the reference data, the formation constants of the aqua-hydroxido complexes [Fe(OH)]2+ and [Fe(OH)2]+ are equal to log β10-1 = −2.68 and log β10-2 = −6.48, respectively [15,16,17,18,19].
Figure 2c shows the course of spectrophotometric titration in the range of pH = 0.97–2.04 at wavelengths of 300–500 nm. The Fe(III)-ceftazidime complexes are formed in a very acidic medium (at pH < 1.0) just at the beginning of titration. The absence of an absorption band at about 337 nm, at the pH 0.97—characteristic of free Fe(III) ions (Figure 2d)—is evidence of the formation of complexes. Above pH 2.0, a precipitate appears.
Calculations based on potentiometric titrations in the presence of the metal ion at a pH of approximately 2.00 confirmed the formation of the [FeLH2]4+ complex in an aqueous solution. The value of the determined overall stability constant is log β [FeLH2]4+ = 11.88 {Fe3++2H++L = [FeLH2]4+}. The related stability constant is equal to log K FeLH 2 4 + Fe = 11.88 7.62 = 4.26 based on the equation log K FeLH 2 4 + Fe = log β 112 log β 012 . In the literature, the values of the stability constants for Ni(II) and Cu(II) ions with ceftazidime are log β NiCtzd+ = 4.04 and log β Ni(Ctzd)2 = 6.41, log β CuCtzd+ = 5.03, respectively [13]. In the Hyperquad model were used the dissociation constants of ceftazidime, previously determined by pH-metric titration (log β [LH3]2+ = 9.23, log β [LH2]+ = 7.62, log β [LH] = 4.82) [13], where [LH3]2+ non-deprotonated all active groups, viz., two carboxyl (at the six-membered dihydrothiazine ring and at the methyl-ethoxy group), amine, and amide groups; [LH2]+ deprotonated a carboxyl group at the six-membered dihydrothiazine ring; and [LH] deprotonated two carboxyl groups. The hydrolysis constants of Fe(III) (log β [Fe(OH)]2+ = −2.68; log β [Fe(OH)2]+ = −6.48) were taken from the data [15]. The ionic product of water pKw included in the equilibrium model was 13.77 [20]. The additional protonated and deprotonated complexes introduced to the equilibrium model were rejected during the procedure refinement. Figure 2d shows a representative species distribution for the Fe(III)-ceftazidime system based on the potentiometric determination of both the overall protonation constants of ceftazidime [13] and the stability constant of the complex.
We read in the literature that similar [Fe2(ceftazidime)3Cl2(H2O)(OH)] complexes have been synthesized, but in a solid product. A solution of ceftazidime and Fe(III) was added to hot ethanol. The solution was refluxed, filtered, and dried, which led to the formation of a solid product [21]. In the work are given physical measurements and analytical data of the complexes (elemental analysis, colour). The conformational changes and binding of ceftazidime in response to transition metals were identified by IR, electronic spectra, ESR, and magnetic susceptibility. Also, thermal analysis of ceftazidime and its metal complexes was conducted based on thermo-gravimetric and differential analysis curves. The mechanism of decomposition and kinetic parameters were evaluated. From magnetic measurement and spectral data, octahedral structures were proposed for permanent Fe(III)-ceftazidime complexes. The authors of the article also stated that ceftazidime complexes show higher positive antibacterial activity compared to antifungal activity. Other studies indicate the detrimental effects of iron overload in the setting of viral infections: the viruses seem to prosper in the presence of unbound iron. Therefore, iron chelation appears to be a potential and logical beneficial adjuvant therapy for viral infections in an era of multidrug-resistant viruses [22]. The pathogens require iron as a nutrient; iron deprivation serves as an innate immune mechanism against invading pathogens [23]. On the bases of Overtone’s concept and chelation theory, most metal complexes have higher activity than free ligands [24]. Thus, it can also be assumed that the activity of Fe(III)-ceftazidime complexes in an aqueous solution will be higher than that of commercial ceftazidime.
The UV-vis spectrophotometric and potentiometric methods confirmed the possibility of forming a mononuclear complex in a mixture of ceftazidime with Fe(III) ions in an acidic medium. The results of our research could be helpful in identifying active sites of biomolecules, determining metal–ligand coordination, and designing biochemical syntheses, drugs, and biomarkers in medicine.

3. Materials and Methods

3.1. Reagents

Ceftazidime ((6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetamido)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate) was obtained from Sigma-Aldrich (St. Louis, MO, USA). Carbonate-free 1.0 M NaOH solution was purchased from J.T. Baker (Radnor, PA, USA). Perchloric acid solution from Laborchemie Apolda (Apolda, Germany) was standardized by titrations with NaOH. A standard solution of sodium perchlorate monohydrate (Laborchemie Apolda, Germany) was used to adjust the ionic medium. Argon of high purity (Linde, Dublin, Ireland) was used. Iron(III) chloride was obtained from Sigma-Aldrich, and 1.0 M HCl solution was prepared from concentrated hydrochloric acid (Avantor Performance Materials, Gliwice, Poland). All solutions were prepared in double-distilled water.

3.2. Spectrophotometric Measurements

Electronic spectra under argon were recorded on a Cary 50 Bio spectrophotometer, equipped with a fibre-optic device (with a path length of 1 cm, 5 mm), (Varian Pty. Ltd., Mulgrave, Australia). This enabled the study of equilibrium systems spectrophotometrically, simultaneously with pH measurements controlled by a Titrando 905 automatic titration (Metrohm, Herisau, Appenzell Ausserrhoden, Switzerland) kit with a combined InLab Semi-Micro (Mettler Toledo, Columbus, OH, USA) polymer microelectrode. Due to the highly disturbing absorption of the nitrate ion at about 300 nm, all the UV experiments were carried out in a perchlorate medium, which was enabled by a combined polymer microelectrode. The ionic strength (I = 1.0 M) was adjusted with NaClO4. The electrode was calibrated with buffers at pH 4.00 and 7.00 before use. The fibre-optic probe, 5 mm long, corresponding to a path length of 1 cm, was dipped directly into the thermostated titration vessel (a constant temperature of 25.0 ± 0.1 °C was maintained). A stream of pure argon was passed over the sample surface to obtain oxygen and carbon dioxide solutions freely. After each addition of carbonate-free NaOH and an appropriate time delay to equilibrate the system, the pH and EMF were controlled. The spectrum was recorded with a slow scan (300 nm min−1) at selected pH values.
The tests were first performed for the metal in the absence of the ligand (the total concentration of FeCl3 ∙ 6H2O was equal to 1.8·10−3 mol·L−1). Next, the ligand was examined in the absence of the metal (the total concentration of ceftazidime was equal to 1.0·10−5 mol·L−1). The solutions containing Fe(III) ions and ceftazidime were prepared with a ligand–metal molar ratio of 2:1 for two samples of the solution (the total metal concentrations were 1.8·10−3 mol·L−1 and 3.6·10−4 mol·L−1, respectively), and with a ligand–metal molar ratio of 1:2 (the total metal concentration was 7.1·10−4 mol·L−1). UV-vis spectra were recorded in the range of 200–900 nm, in an aqueous solution, and ionic strength I = 1.0 M (NaClO4). The studies were carried out at 25.0 ± 0.1 °C in a closed thermostated vessel, in anaerobic conditions under argon. The titrations were performed with the carbonate-free 1.0 M NaOH.

3.3. pH-Metric Titrations

Potentiometric titrations were conducted by using an automatic titrator system, the Titrando 905 (Metrohm, Herisau, Appenzell Ausserrhoden, Switzerland). An LL Biotrode combined glass electrode (Metrohm, Herisau, Appenzell Ausserrhoden, Switzerland) was calibrated with NaOH regarding the hydrogen ion concentration [25]. The solution of the acid was calibrated alkalimetrically and determined by the Gran method [26,27]. The measurements were carried out in a thermostated vessel at a constant temperature of 25.0 ± 0.1 °C and an ionic strength of 0.5 M (KCl). All titrations were carried out in aqueous solutions in 4 mL samples. Pure argon was passed over the solution surface.
The system was tested at ceftazidime–Fe(III) molar ratios of 5:1 and 10:1 at a pH of approximately 2.00 (the total concentration of ceftazidime was equal to 3.6 × 10−3 M) (Figure S1). The fitting procedure using the Hyperquad 2013 software allowed the calculation of the concentration formation constants according to the formula: βmlh = [MmLlHh]/[M]m[L]l[H]h. The goodness of fit was checked by the objective function U = Σi=1,m Wi ri2, where W is the weight, r is a residual (equal to the difference between observed and calculated EMF values), m is the number of experimental points, and n is the number of refined parameters. The weighting factor Wi is defined as the reciprocal of the estimated variance of measurements, dependent on the estimated variances of EMF and volume readings. The value of the normalized sum of squared residuals, δ = U/(m − n), was compared with the χ2 (chi-squared) test of randomness at a number of degrees of freedom equal to m − n [28]. The speciation diagrams were simulated via the HySS 2009 software [29].

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/molecules27217226/s1: Figure S1: The pH-titration curves for the Fe(III)-ceftazidime system, with a ligand–Fe(III) molar ratio of 5:1, Cceftazidime = 3.6 × 10−3 M.

Author Contributions

Conceptualization, M.P. and J.F.; investigation, M.P. and M.W.; supervision, M.P. and J.F.; writing—original draft, M.P.; writing—review and editing, M.W. and J.F. All authors have read and agreed to the published version of the manuscript.

Funding

Financial support of this work by the Medical University of Lodz (Statutory Fund No. 503/3-014-02/503-31-001–Mirosława Świątek; Statutory Fund No. 503/1-156-04/503-11-001-19–Jakub Fichna) is gratefully acknowledged.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We offer our thanks to Amira El Qaisi, Joanna Gądek-Sobczyńska, and Aleksander Kufelnicki.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Zhong, F.; Li, C.; Xie, Y.; Xu, H.; Gao, J. Titanium metal-organic framework nanorods for highly sensitive nitroaromatic explosives detection and nanomolar sensing of Fe3+. J. Solid State Chem. 2019, 278, 120892. [Google Scholar] [CrossRef]
  2. Drakesmith, H.; Prentice, A. Viral infection and iron metabolism. Nat. Rev. Microbiol. 2008, 6, 541–552. [Google Scholar] [CrossRef] [PubMed]
  3. Thomson, A.M.; Rogers, J.T.; Leedman, P.J. Iron-regulatory proteins, iron-responsive elements and ferritin mRNA translation. Int. J. Biochem. Cell Biol. 1999, 31, 1139–1152. [Google Scholar] [CrossRef]
  4. Tripathy, S.K.; Woo, J.Y.; Han, C.-S. Colorimetric detection of Fe(III) ions using label-free gold nanoparticles and acidic thiourea mixture. Sens. Actuators B Chemical. 2013, 181, 114–118. [Google Scholar] [CrossRef]
  5. Umbreit, J. Iron deficiency: A concise review. Am. J. Hematol. 2005, 78, 225–231. [Google Scholar] [CrossRef]
  6. Andrews, N.C. Iron metabolism: Iron deficiency and iron overload. Annu. Rev. Genom. Human Genet. 2000, 1, 75–98. [Google Scholar] [CrossRef]
  7. Asbel, L.E.; Levison, M.E. Cephalosporins, Carbapenems, and Monobactams. Infect. Dis. Clin. N. Am. 2000, 14, 435–447. [Google Scholar] [CrossRef]
  8. Christ, W. Pharmacological Properties of Cephalosporins. Infection 1991, 19, S244–S252. [Google Scholar] [CrossRef]
  9. Magnet, S.; Arbeloa, A.; Mainardi, J.L.; Hugonnet, J.E.; Forgeaud, M.; Dubost, L.; Marie, A.; Delfosse, V.; Mayer, C.; Rice, L.B.; et al. Specificity of L,D-Transpeptidases from Gram-positive Bacteria Producing Different Peptidoglycan Chemotypes. J. Biol. Chem. 2007, 282, 13151–13159. [Google Scholar] [CrossRef] [Green Version]
  10. Bergan, T. Pharmacokinetic Properties of the Cephalosporins. Drugs 1987, 34, 89–104. [Google Scholar] [CrossRef]
  11. Anacona, J.R.; Patiño, C. Metalloantibiotics: Synthesis and antibacterial activity of ceftazidime metal complexes. J. Coord. Chem. 2009, 64, 613–621. [Google Scholar] [CrossRef]
  12. Tarinc, D.; Muslu, H.; Cesme, M.; Golcu, A.; Tumer, M.; Ozkan, A.S. Synthesis, structural characterization and electrochemical evaluation of Schiff base transition metal complexes with ceftazidime. Curr. Anal. Chem. 2013, 9, 319–332. [Google Scholar] [CrossRef]
  13. Alekseev, V.G.; Sokolova, E.M. Experimental Study and Computer Modeling of Ni(II) and Cu(II) Complexation with Ceftazidime. Russ. J. Inorg. Chem. 2016, 61, 531–534. [Google Scholar] [CrossRef]
  14. Sanli, S.; Sanli, N.; Gumustas, M.; Ozkan, A.S.; Karadas, N.; Aboul-Enein, H.Y. Simultaneous Estimation of Ceftazidime and Ceftizoxime in Pharmaceutical Formulations by HPLC Method. Chromatographia 2011, 74, 549–558. [Google Scholar] [CrossRef]
  15. Wozźniczka, M.; SŚwiątek, M.; Gądek-Sobczynńska, J.; Pasternak, B.; Kufelnicki, A. Spectroscopic Determination of Metal-Ligand Coordination by Biologically Active 2-Picolinehydroxamic Acid with Iron(III) and Oxidovanadium(IV) in Aqueous Solutions. Acta Chim. Slov. 2019, 66, 711–718. [Google Scholar] [CrossRef] [PubMed]
  16. Torres, J.; Domínguez, S.; Cerdá, M.F.; Obal, G.; Mederos, A.; Irvine, R.F.; Díaz, A.; Kremer, C. Solution behaviour of myo-inositol hexakisphosphate in the presence of multivalent cations. Prediction of a neutral pentamagnesium species under cytosolic/nuclear conditions. J. Inorg. Biochem. 2005, 99, 828–840. [Google Scholar] [CrossRef]
  17. Khoe, G.H.; Brown, P.L.; Sylva, R.N.; Robins, R.G. The hydrolysis of metal ions. Part 9. Iron(III) in perchlorate, nitrate, and chloride media (1 mol dm–3). J. Chem. Soc. Dalton Trans. 1986, 9, 1901–1906. [Google Scholar] [CrossRef]
  18. Iuliano, M.; De Tommaso, G. Interaction of Iron(III) with 2-Hydroxybenzohydroxamic Acid in Aqueous Solutions. J. Chem. Eng. Data. 2010, 55, 400–404. [Google Scholar] [CrossRef]
  19. Perera, W.N.; Hefter, G. Mononuclear Cyano- and Hydroxo-Complexes of Iron(III). Inorg. Chem. 2003, 42, 5917–5923. [Google Scholar] [CrossRef]
  20. Pettit, L.D.; Powell, K.J. Stability Constants Database, IUPAC and Academic Software; Royal Society of Chemistry: London, UK, 1993. [Google Scholar]
  21. Masoud, M.S.; Ali, A.E.; Elasala, G.S.; Kolkaila, S.A. Synthesis, spectroscopic, biological activity and thermal characterization of ceftazidime with transition metals. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2018, 193, 458–466. [Google Scholar] [CrossRef]
  22. Schmidt, S.M. The role of iron in viral infections. Front. Biosci. 2020, 25, 893–911. [Google Scholar] [CrossRef] [PubMed]
  23. Cassat, J.E.; Skaar, E.P. Iron in infection and immunity. Cell Host Microbe 2013, 13, 509–519. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Kirubavathy, S.J.; Velmurugan, R.; Parameswari, K.; Chitra, S. Synthesis, Characterization and Biological Evaluation of Cu(Ii), Co(III) and Fe(III) Complexes of 2-Benzoyl-3-(Nitrophenyl)Quinoxaline. Int. J. Pharm. Sci. 2014, 5, 2508–2517. [Google Scholar] [CrossRef]
  25. Irving, H.; Miles, M.G.; Pettit, L.D. A study of some problems in determining the stoicheiometric proton dissociation constants of complexes by potentiometric titrations using a glass electrode. Anal. Chim. Acta 1967, 38, 475–488. [Google Scholar] [CrossRef]
  26. Gans, P.; O’Sullivan, B. GLEE, a new computer program for glass electrode calibration. Talanta 2000, 51, 33–37. [Google Scholar] [CrossRef]
  27. Gamov, G.A.; Yarullin, D.N.; Gudyrina, M.A.; Pogodina, E.I.; Medvedeva, A.S.; Zavalishin, M.N. Protonation of L-Ascorbic Acid in an Aqueous Solution at T = 298.2 K, p = 0.1 MPa, and I = 0.10−5.0 mol L1 (NaCl). J. Chem. Eng. Data 2022, 67, 1358–1364. [Google Scholar] [CrossRef]
  28. Gans, P.; Sabatini, A.; Vacca, A. Investigation of equilibria in solution. Determination of equilibrium constants with the Hyperquad suite of programs. Talanta 1996, 43, 1739–1753. [Google Scholar] [CrossRef]
  29. Alderighi, L.; Gans, P.; Ienco, A.; Peters, D.; Sabatini, A.; Vacca, A. Hyperquad simulation and speciation (HySS): A utility program for the investigation of equilibria involving soluble and partially soluble species. Coord. Chem. Rev. 1999, 184, 311–318. [Google Scholar] [CrossRef]
Figure 1. Structure of ceftazidime.
Figure 1. Structure of ceftazidime.
Molecules 27 07226 g001
Figure 2. (a) UV spectra of ceftazidime within the pH range of 1.82–12.03, Cceftazidime = 1.0·10−5 M; (b) UV-vis spectra of Fe(III) ions within the pH range of 0.97–2.04, C FeCl 3 · 6 H 2 O = 1.8∙10−3 M; (c) UV-vis absorption spectra of the Fe(III)-ceftazidime system, within the pH range of 0.97–2.04; C FeCl 3 · 6 H 2 O = 1.8·10−3 M, Cceftazidime = 3.6·10−3 M; (d) The distribution diagram of species as a function of pH for the complex formed in the Fe(III)-ceftazidime system at a ligand–Fe(III) molar ratio of 5:1, Cceftazidime = 3.6·10−3 M obtained from potentiometric data.
Figure 2. (a) UV spectra of ceftazidime within the pH range of 1.82–12.03, Cceftazidime = 1.0·10−5 M; (b) UV-vis spectra of Fe(III) ions within the pH range of 0.97–2.04, C FeCl 3 · 6 H 2 O = 1.8∙10−3 M; (c) UV-vis absorption spectra of the Fe(III)-ceftazidime system, within the pH range of 0.97–2.04; C FeCl 3 · 6 H 2 O = 1.8·10−3 M, Cceftazidime = 3.6·10−3 M; (d) The distribution diagram of species as a function of pH for the complex formed in the Fe(III)-ceftazidime system at a ligand–Fe(III) molar ratio of 5:1, Cceftazidime = 3.6·10−3 M obtained from potentiometric data.
Molecules 27 07226 g002
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Pająk, M.; Woźniczka, M.; Fichna, J. Complex-Forming Properties of Ceftazidime with Fe(III) Ions in an Aqueous Solution. Molecules 2022, 27, 7226. https://doi.org/10.3390/molecules27217226

AMA Style

Pająk M, Woźniczka M, Fichna J. Complex-Forming Properties of Ceftazidime with Fe(III) Ions in an Aqueous Solution. Molecules. 2022; 27(21):7226. https://doi.org/10.3390/molecules27217226

Chicago/Turabian Style

Pająk, Marek, Magdalena Woźniczka, and Jakub Fichna. 2022. "Complex-Forming Properties of Ceftazidime with Fe(III) Ions in an Aqueous Solution" Molecules 27, no. 21: 7226. https://doi.org/10.3390/molecules27217226

APA Style

Pająk, M., Woźniczka, M., & Fichna, J. (2022). Complex-Forming Properties of Ceftazidime with Fe(III) Ions in an Aqueous Solution. Molecules, 27(21), 7226. https://doi.org/10.3390/molecules27217226

Article Metrics

Back to TopTop